Retrotope

Check out this article from ALS News Today on Retrotope's rapid enrollment of its ongoing Phase 2 trial of RT001 for the treatment of amyotrophic lateral sclerosis (#ALS). The piece offers great context on the ongoing study, as well as how the mechanism of action for RT001 may be able to help patients with neurodegenerative diseases such as ALS. #rarediseases #LouGehrig https://alsnewstoday.com//retrotope-phase-2-trial-rt001-f/

Despite an ongoing global pandemic, Retrotope successfully exceeded its target enrollment numbers for its Phase 2 ALS study of RT001 in less than six weeks. That rapid enrollment speaks to the desperate need for new ALS treatments, as well as the excitement around RT001’s unique mechanism for combatting this devastating disease. A big thank you to the patients and study investigators who are making this study possible. #ALS #LouGehrig #rarediseases https://www.retrotope.com/completion-of-enrollment-in-phase

We appreciate #TRICALS helping raise awareness of the initiation of our Phase 2 clinical study of RT001 in #ALS in Europe. A special thank you to the world-class clinical investigators who are making this trial possible. #LouGehrig #rarediseases https://www.tricals.org//retrotope-announces-initiation-o/

Today marks a key milestone in Retrotope’s efforts to develop a novel treatment to address the unmet needs of patients with ALS. This morning, we announced that the first several patients have been dosed in our Phase 2 ALS study of RT001. Enrollment is proceeding rapidly and we expect to have a data readout from the trial by the end of 2021. #ALS #LouGehrig #rarediseases

The team at Friedreich’s Ataxia News helped spread the word about Retrotope's recent rare pediatric disease designation and Fast Track designation for RT001 in FA. Our pivotal Phase 2/3 trial of RT001 in FA is fully enrolled and we expect data from the study by the end of 2021. #friedreichsataxia #rarediseases https://friedreichsataxianews.com//rt001-fda-rare-pediatr/